Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease

Identifieur interne : 002202 ( PascalFrancis/Curation ); précédent : 002201; suivant : 002203

Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease

Auteurs : Joseph H. Friedman [États-Unis] ; Guido Alves [Norvège] ; Peter Hagell [Suède] ; Johan Marinus [Pays-Bas] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni]

Source :

RBID : Pascal:10-0288337

Descripteurs français

English descriptors

Abstract

Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.
pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 25
A06       @2 7
A08 01  1  ENG  @1 Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease
A11 01  1    @1 FRIEDMAN (Joseph H.)
A11 02  1    @1 ALVES (Guido)
A11 03  1    @1 HAGELL (Peter)
A11 04  1    @1 MARINUS (Johan)
A11 05  1    @1 MARSH (Laura)
A11 06  1    @1 MARTINEZ-MARTIN (Pablo)
A11 07  1    @1 GOETZ (Christopher G.)
A11 08  1    @1 POEWE (Werner)
A11 09  1    @1 RASCOL (Olivier)
A11 10  1    @1 SAMPAIO (Cristina)
A11 11  1    @1 STEBBINS (Glenn)
A11 12  1    @1 SCHRAG (Anette)
A14 01      @1 NeuroHealth, Parkinson's Disease and Movement Disorders Center @2 Warwick, Rhode Island @3 USA @Z 1 aut.
A14 02      @1 Department of Neurology, Warren Alpert Medical School, Brown University @2 Rhode Island @3 USA @Z 1 aut.
A14 03      @1 The Norwegian Centre for Movement Disorders, Stavanger University Hospital @2 Stavanger @3 NOR @Z 2 aut.
A14 04      @1 Department of Neurology, Stavanger University Hospital @2 Stavanger @3 NOR @Z 2 aut.
A14 05      @1 Department of Neurology, Lund University Hospital @2 Lund @3 SWE @Z 3 aut.
A14 06      @1 Department of Neurology, Leiden University Medical Center @2 Leiden @3 NLD @Z 4 aut.
A14 07      @1 Department of Psychiatry Johns Hopkins Hospital @2 Baltimore, Maryland @3 USA @Z 5 aut.
A14 08      @1 Department of Neurology, Johns Hopkins Hospital @2 Baltimore, Maryland @3 USA @Z 5 aut.
A14 09      @1 Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 5 aut.
A14 10      @1 Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health @2 Madrid @3 ESP @Z 6 aut.
A14 11      @1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 7 aut. @Z 11 aut.
A14 12      @1 Department of Neurology, Innsbruck Medical University @2 Innshruck @3 AUT @Z 8 aut.
A14 13      @1 ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse @2 Toulouse @3 FRA @Z 9 aut.
A14 14      @1 Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa @3 PRT @Z 10 aut.
A14 15      @1 Department of Clinical Neurosciences, Institute of Neurology, University College London @3 GBR @Z 12 aut.
A20       @1 805-822
A21       @1 2010
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000193040220010
A44       @0 0000 @1 © 2010 INIST-CNRS. All rights reserved.
A45       @0 142 ref.
A47 01  1    @0 10-0288337
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Maladie de Parkinson @2 NM @5 01
C03 01  X  ENG  @0 Parkinson disease @2 NM @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @2 NM @5 01
C03 02  X  FRE  @0 Pathologie du système nerveux @5 02
C03 02  X  ENG  @0 Nervous system diseases @5 02
C03 02  X  SPA  @0 Sistema nervioso patología @5 02
C03 03  X  FRE  @0 Fatigue @5 09
C03 03  X  ENG  @0 Fatigue @5 09
C03 03  X  SPA  @0 Fatiga @5 09
C03 04  X  FRE  @0 Recommandation @5 10
C03 04  X  ENG  @0 Recommendation @5 10
C03 04  X  SPA  @0 Recomendación @5 10
C03 05  X  FRE  @0 Force @5 11
C03 05  X  ENG  @0 Force @5 11
C03 05  X  SPA  @0 Fuerza @5 11
C07 01  X  FRE  @0 Pathologie de l'encéphale @5 37
C07 01  X  ENG  @0 Cerebral disorder @5 37
C07 01  X  SPA  @0 Encéfalo patología @5 37
C07 02  X  FRE  @0 Syndrome extrapyramidal @5 38
C07 02  X  ENG  @0 Extrapyramidal syndrome @5 38
C07 02  X  SPA  @0 Extrapiramidal síndrome @5 38
C07 03  X  FRE  @0 Maladie dégénérative @5 39
C07 03  X  ENG  @0 Degenerative disease @5 39
C07 03  X  SPA  @0 Enfermedad degenerativa @5 39
C07 04  X  FRE  @0 Pathologie du système nerveux central @5 40
C07 04  X  ENG  @0 Central nervous system disease @5 40
C07 04  X  SPA  @0 Sistema nervosio central patología @5 40
N21       @1 186
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:10-0288337

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</title>
<author>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1>
<s2>Warwick, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1>
<s2>Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Neurology, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
</affiliation>
</author>
<author>
<name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name>
<affiliation wicri:level="1">
<inist:fA14 i1="05">
<s1>Department of Neurology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author>
<name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Department of Neurology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Psychiatry Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="08">
<s1>Department of Neurology, Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="12">
<s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innshruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1">
<inist:fA14 i1="13">
<s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1">
<inist:fA14 i1="14">
<s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author>
<name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1">
<inist:fA14 i1="15">
<s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288337</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288337 INIST</idno>
<idno type="RBID">Pascal:10-0288337</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B17</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002202</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</title>
<author>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1>
<s2>Warwick, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1>
<s2>Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Neurology, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
</affiliation>
</author>
<author>
<name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name>
<affiliation wicri:level="1">
<inist:fA14 i1="05">
<s1>Department of Neurology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author>
<name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Department of Neurology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Psychiatry Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="08">
<s1>Department of Neurology, Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="12">
<s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innshruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1">
<inist:fA14 i1="13">
<s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1">
<inist:fA14 i1="14">
<s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author>
<name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1">
<inist:fA14 i1="15">
<s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Fatigue</term>
<term>Force</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Recommendation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Fatigue</term>
<term>Recommandation</term>
<term>Force</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Recommandation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>25</s2>
</fA05>
<fA06>
<s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>FRIEDMAN (Joseph H.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>ALVES (Guido)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>HAGELL (Peter)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>MARINUS (Johan)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="10" i2="1">
<s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="11" i2="1">
<s1>STEBBINS (Glenn)</s1>
</fA11>
<fA11 i1="12" i2="1">
<s1>SCHRAG (Anette)</s1>
</fA11>
<fA14 i1="01">
<s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1>
<s2>Warwick, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1>
<s2>Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Neurology, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Department of Neurology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Department of Neurology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Department of Psychiatry Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08">
<s1>Department of Neurology, Johns Hopkins Hospital</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="09">
<s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="10">
<s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="11">
<s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12">
<s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innshruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="13">
<s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="14">
<s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="15">
<s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20>
<s1>805-822</s1>
</fA20>
<fA21>
<s1>2010</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000193040220010</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>142 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>10-0288337</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Fatigue</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Fatigue</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Fatiga</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Recommandation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Recommendation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Recomendación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Force</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Force</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Fuerza</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21>
<s1>186</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002202 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002202 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0288337
   |texte=   Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024